喜炎平与利巴韦林治疗小儿上呼吸道感染疗效及安全性比较

The Comparison of Effect and Security of Xiyanping Injection and Ribavirin Therapy on Acute Upper Respiratory Infections In children

目的比较喜炎平注射液与常规西医疗法对小儿上呼吸道感染的疗效及安全性。方法将156例急性上呼吸道感染患儿随机分为两组,每组78例。治疗组予喜炎平注射液静滴;对照组予利巴韦林注射液静滴。比较两组退热及症状消失时间、血清炎症因子水平变化、总体疗效及不良反应。结果治疗组退热时间,鼻塞流涕、咳嗽、呕吐、腹泻及咽喉红肿消失时间均显著短于对照组(P<0.01)。两组患儿治疗后血清TNF-α及IL-6水平均较治疗前显著降低,且治疗组降低幅度显著大于对照组(P<0.01)。治疗组的痊愈率及总有效率均显著高于对照组(P<0.05)。治疗组未发生明显不良反应,对照组发生上腹部疼痛2例,恶心呕吐2例,面部皮肤红疹1例。结论与常规西医治疗比较,喜炎平可更好地改善小儿急性上呼吸道感染的临床症状、缩短发热及症状消失时间,并可显著降低血清炎症因子TNF-αI、L-6的水平,安全有效,值得临床推广。

Objective To compare effect and security of xiyanping injection and ribavirin therapy on acute upper respiratory infections in children. Methods 156 cases of children with acute upper respirato- ry infections were randomly divided into two groups. The treatment group received xiyanping injection, while the control group received ribavirin injection. The disappearing time of fever and symptoms, levels of serum inflammatory factor, overall effective rate and adverse reactions of the two groups were com- pared. Results The disappearing time of fever, nasal obstruction, rhinorrhoea, cough, vomiting, diar- rhea and throat irritation in treatment group were obviously shorter than that in control group（P 〈0.01 ）. The levels of TNF-α and IL-6 after treatment in both groups decreased obviously than that before treat- ment, and the decreasing degree in treatment group was larger than that in control group（P 〈 0.01 ）. The cure rate and overall response rate in treatment group were obviously higher than that in control group（P 〈 0.05）. There was no adverse reaction in treatment group, while there were 2 cases of upper abdominal pain, 2 cases of nausea and vomiting, 1 case of facial skin rash in control group. Conclusion Compared with routine western therapy, xiyanping injection can better improve the symptoms of acute upper respira- tory infections in children, shorten the disappearing time of fever and symptom, and decrease the levels of TNF-α and IL-6. It was effective with high security, and worthy of clinical promotion.